Is it safe to administer an inactivated influenza vaccine to a patient taking methotrexate 15 mg weekly, and should the methotrexate be temporarily held around vaccination?

Influenza Vaccination in Patients on Methotrexate 15 mg Weekly

Administer the inactivated influenza vaccine immediately and hold methotrexate for 2 weeks after vaccination if disease activity permits. 1

Vaccine Safety and Administration

• Inactivated influenza vaccines are safe to administer to patients taking methotrexate at any dose, including 15 mg weekly. 1
• The vaccine should be given on schedule during flu season—do not delay vaccination while deciding about methotrexate management. 1
• If you are uncertain about holding methotrexate, vaccinate first and consult with the patient's rheumatologist afterward rather than miss the vaccination opportunity. 1

Methotrexate Management Strategy

The 2023 American College of Rheumatology provides clear guidance:

• Hold methotrexate for 2 weeks after influenza vaccination if the patient's rheumatic disease activity allows. 1
• This recommendation is specifically for influenza vaccination—methotrexate should be continued for other non-live vaccines. 1

Evidence Supporting Methotrexate Hold

The rationale for holding methotrexate is robust:

• Two randomized controlled trials demonstrate that holding methotrexate significantly improves vaccine immunogenicity. 1
• A 2018 RCT showed that patients who held methotrexate for 2 weeks after vaccination achieved satisfactory vaccine response (≥4-fold antibody increase to ≥2 strains) in 75.5% versus 54.5% in those who continued methotrexate (p<0.001). 2
• Seroprotection rates were 10-16% higher across all four influenza strains when methotrexate was held. 2
• At the 15 mg weekly dose your patient is receiving, methotrexate significantly blunts—but does not completely eliminate—vaccine response. 1

Duration of Hold: 1 Week vs 2 Weeks

Recent evidence suggests flexibility in hold duration:

• A 2023 RCT demonstrated that holding methotrexate for 1 week after vaccination was non-inferior to holding for 2 weeks (68.9% vs 75.0% satisfactory response, p=0.364). 3
• However, the ACR guideline continues to recommend the 2-week hold based on the stronger evidence from earlier trials. 1
• For patients at higher flare risk, consider the 1-week hold as a reasonable alternative based on the 2023 data. 3

Disease Flare Risk Assessment

Critical consideration before holding methotrexate:

• Disease flare rates increased modestly when methotrexate was held: 10.6% versus 5.1% in one study (p=0.07). 1
• Another trial showed flare rates of 34-39% when methotrexate was held versus 24% when continued, though this difference was not statistically significant. 4
• If the patient has highly active or unstable rheumatic disease, continue methotrexate and accept the reduced vaccine response rather than risk a significant flare. 1
• Shared decision-making with the patient about flare risk versus vaccine efficacy is essential. 1

Clinical Algorithm

Follow this decision pathway:

1. Assess current disease activity:

   • Stable/low activity → Proceed with methotrexate hold
   • Active/unstable disease → Continue methotrexate, accept reduced vaccine response

2. Administer influenza vaccine immediately (do not delay for flu season timing). 1

3. If disease activity permits:

   • Hold methotrexate for 2 weeks after vaccination (standard approach) 1
   • OR hold for 1 week if flare risk is concerning (alternative based on recent evidence) 3

4. Resume methotrexate at the same dose (15 mg weekly) after the hold period. 2

5. Monitor for disease flare during and after the methotrexate hold period. 2

Important Caveats

• This recommendation applies only to influenza vaccination—for pneumococcal, COVID-19, and other vaccines, methotrexate should generally be continued. 1
• Concomitant low-dose glucocorticoids (≤10 mg prednisone daily) do not require dose adjustment and do not significantly impair vaccine response. 1
• The improved immunogenicity from holding methotrexate is clinically meaningful but does not guarantee complete protection—some patients will still have suboptimal responses. 1